Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection

Hepatology

Volumn 62, Issue 4, 2015, Pages 1013-1023

  Pawlotsky, Jean Michel ^a,b   Flisiak, Robert ^c   Sarin, Shiv K ^d   Rasenack, Jens ^e   Piratvisuth, Teerha ^f   Chuang, Wan Long ^g   Peng, Cheng Yuan ^h   Foster, Graham R ⁱ   Shah, Samir ^j   Wedemeyer, Heiner ^k   Hézode, Christophe ^a,b   Zhang, Wei ^l   Wong, Kelly A ^m   Li, Bin ^m   Avila, Claudio ^n,o   Naoumov, Nikolai V ⁿ  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM U955   (France)

^c MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^d INSTITUTE OF LIVER AND BILIARY SCIENCES   (India)

^e UNIVERSITY OF FREIBURG   (Germany)

^f PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^g KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^h CHINA MEDICAL UNIVERSITY   (Taiwan)

ⁱ QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^j Baldota Institute of Digestive Sciences   (India)

^k HANNOVER MEDICAL SCHOOL   (Germany)

^l Beijing Novartis Pharma Co Ltd   (China)

^m NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

ⁿ NOVARTIS PHARMA AG   (Switzerland)

^o Gilead Sciences   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALISPORIVIR; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; CYCLOSPORIN; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ALOPECIA; ANEMIA; ANXIETY; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CHILL; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; INSOMNIA; INTENTION TO TREAT ANALYSIS; JAUNDICE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MYALGIA; NAUSEA; NEUTROPENIA; PANCREATITIS; PARAMETERS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RAPID VIROLOGICAL RESPONSE; RASH; RECURRENCE RISK; SIDE EFFECT; SOMNOLENCE; STATISTICAL ANALYSIS; SUSTAINED VIROLOGICAL RESPONSE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VIRUS LOAD; WEIGHT REDUCTION; CLASSIFICATION; CLINICAL TRIAL; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED;

ADULT; ANTIVIRAL AGENTS; CYCLOSPORINE; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84942553557     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27960     Document Type: Article

References (34)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-1342.
2. Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011;31(Suppl 2):30-60.
3. Negro F, Alberti A. The global health burden of hepatitis C virus infection. Liver Int 2011;31(Suppl 2):1-3.
4. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-1493.
5. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1594-1603.
6. Goossens N, Negro F. Is the genotype 3 of the hepatitis C virus the new villain? Hepatology 2014;59:2403-2412.
7. Tapper EB, Afdhal NH. Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. J Viral Hepat 2013;20:669-677.
8. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-2617.
9. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124-134.
10. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522-527.
11. Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, Mullhaupt B, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009;51:655-666.
12. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005;54:1003-1008.
13. Probst A, Dang T, Bochud M, Egger M, Negro F, Bochud PY. Role of hepatitis C virus genotype 3 in liver fibrosis progression: a systematic review and meta-analysis. J Viral Hepat 2011;18:745-759.
14. Marcellin P, Cheinquer H, Curescu M, Dusheiko GM, Ferenci P, Horban A, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 2012;56:2039-2050.
15. Shoeb D, Dearden J, Weatherall A, Bargery C, Moreea S, Alam S, et al. Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial. J Hepatol 2014;60:699-705.
16. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-1877.
17. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-1887.
18. Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol 2013;11:482-496.
19. Dorner M, Horwitz JA, Donovan BM, Labitt RN, Budell WC, Friling T, et al. Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature 2013;501:237-241.
20. Gallay PA, Lin K. Profile of alisporivir and its potential in the treatment of hepatitis C. Drug Des Devel Ther 2013;7:105-115.
21. Landrieu I, Hanoulle X, Bonachera F, Hamel A, Sibille N, Yin Y, et al. Structural basis for the non-immunosuppressive character of the cyclosporin A analogue Debio 025. Biochemistry 2010;49:4679-4686.
22. Coelmont L, Hanoulle X, Chatterji U, Berger C, Snoeck J, Bobardt M, et al. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One 2010;5:e13687.
23. Flisiak R, Feinman SV, Jablkowski M, Horban A, Kryczka W, Pawlowska M, et al. The cyclophilin inhibitor Debio 025 combined with PEG-IFN alpha-2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 2009;49:1460-1468.
24. Garcia-Rivera JA, Bobardt M, Chatterji U, Hopkins S, Gregory MA, Wilkinson B, et al. Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir. Antimicrob Agents Chemother 2012;56:5113-5121.
25. Chatterji U, Garcia-Rivera JA, Baugh J, Gawlik K, Wong KA, Zhong W, et al. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance. Antimicrob Agents Chemother 2014;58:3327-3334.
26. Coelmont L, Kaptein S, Paeshuyse J, Vliegen I, Dumont JM, Vuagniaux G, Neyts J. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother 2009;53:967-976.
27. Guedj J, Yu J, Levi M, Li B, Kern S, Naoumov NV, Perelson AS. Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients. Hepatology 2014;59:1706-1714.
28. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-221.
29. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370:1993-2001.
30. Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015;61:1127-1135.
31. Naoumov NV. Cyclophilin inhibition as potential therapy for liver diseases. J Hepatol 2014;61:1166-1174.
32. Dvory-Sobol H, Wyles D, Ouyang W, Chodavarapu K, McNally J, Cheng W, et al. Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. J Hepatol 2015;62(Suppl 1):S221.
33. Krishnan P, Tripathi R, Schnell G, Reisch T, Beyer J, Dekhtyar T, et al. Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir- and dasabuvir-based regimens. J Hepatol 2015;62(Suppl 1):S220.
34. Griffel L, Bao W, Orsenigo R, Guo V, Wu M, Loeffler J, et al. Interferon (IFN)-free alisporivir (ALV) has a better overall safety profile compared to IFN-containing treatment: a pooled analysis of the ALV development program. J Hepatol 2013;58(Suppl 1):S336-S337.